RO7198457

DRUG3 trials

Sponsors

Genentech Inc., Memorial Sloan Kettering Cancer Center, Hoffmann-La Roche

Conditions

Advanced MelanomaNon-small Cell Lung Cancer (NSCLC)Pancreatic Cancer

Phase 1

Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery

Active, not recruitingNCT04161755

Memorial Sloan Kettering Cancer CenterPancreatic Cancer

Start: 2019-12-13End: 2026-11-11Updated: 2026-01-07

Phase 2

A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

WithdrawnNCT04267237

Hoffmann-La RocheNon-small Cell Lung Cancer (NSCLC)

Start: 2021-03-31End: 2025-09-30Updated: 2021-02-04

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of RO7198457 in Combination With Pembrolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma

CompletedCTIS2023-507389-15-00

Genentech Inc.Advanced Melanoma

Start: 2020-02-26End: 2025-01-21Target: 60Updated: 2024-08-20

Related Papers

Abstract PR-06: Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

Cancer Immunology Research2024-10-183 citations

Phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine, for pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2022-06-0131 citations